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Abstract Minimally invasive vertebral augmentation-
based techniques have been used for the treatment of spinal
fractures (osteoporotic and malignant) for approximately
25 years. In this review, we try to give an overview of the
current spectrum of percutaneous augmentation techniques,
safety aspects and indications. Crucial factors for success
are careful patient selection, proper technique and choice
of the ideal cement augmentation option. Most compres-
sion fractures present a favourable natural course, with
reduction of pain and regainment of mobility after a few
days to several weeks, whereas other patients experience a
progressive collapse and persisting pain. In this situation,
percutaneous cement augmentation is an effective treat-
ment option with regards to pain and disability reduction,
improvement of quality of life and ambulatory and pul-
monary function.
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Introduction
Osteoporotic fractures of the spine affect 1.4 million people
per year worldwide and are an economic burden for many
health care systems [1]. Besides typical pain, they can lead
to a significant reduction of physical function and increased
morbidity and mortality [2–4]. In some cases, non-surgical
conservative treatment has no or just minimal clinical
effect, resulting in the progression of deformity, persisting
pain and/or significant reduction of quality of life (QoL).
Minimally invasive vertebral augmentation-based tech-
niques [e.g. vertebroplasty (VP) and kyphoplasty (KP)]
have been used for the treatment of spinal fractures (oste-
oporotic and malignant) for approximately 25 years. Pre-
viously used in open tumour surgery to refill the bony
defect in the vertebral body [5], the percutaneous appli-
cation of polymethylmethacrylate bone cement (PMMA)
was first described by Galibert et al. for the treatment of
vertebral angiomas [6]. Since then, the technique was
adapted to its present form.
In this review, we try to give an overview of the current
spectrum of percutaneous augmentation techniques, safety
aspects and indications.
Indications
Most compression fractures present a favourable natural
course, with reduction of pain and regainment of mobility
after a few days. After the initial diagnosis of a vertebral
compression fracture (VCF) we, therefore, recommend to
always first try a conservative treatment with sufficient
analgesia and support in mobilisation. Seven to ten days
after the onset of pain, we perform a clinical and radio-
logical control by a spine specialist to assess whether the
kyphotic deformity is progressive under load and if the
pain shows a mechanical quality as a hint for persisting
fracture mobility. Given a relevant progression of defor-
mity, persisting pain and poor bone quality, a percutaneous
intervention can be indicated, as there is a high chance that
the final result will be a relevant kyphotic deformity. Many
of these aged patients with concomitant sarcopaenia and
otherwise rigid spines are limited in compensating this
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sagittal dysbalance. Other fractures show a persisting
mobility or cause neurological symptoms by secondary
bony stenosis of the spinal canal. Prior to any intervention,
a computed tomography (CT) or magnetic resonance
imaging (MRI) scan in the supine position should be per-
formed in order to rule out malignancy or a more complex
fracture. Furthermore, intraosseous clefts with vacuum sign
can be observed on CT as an indication of persisting
mobility and potential for active restoration of lordosis.
Which of the techniques described below is to be
applied is dependent on the fracture type and location, bone
quality and the patient’s activity. Simple compression
fractures Magerl type A1 can be treated with a stand-alone
cementation technique. In the case of a relevant kyphotic
deformity, especially if located at the thoracolumbar
junction, and insufficient spontaneous reposition by posi-
tioning in prone lordosis, a balloon kyphoplasty (BKP) or
lordoplasty (or combinations) can be performed. Vertebral
body stents (VBS) are extremely powerful and an expan-
sion beyond the vertebra or into the disc, respectively,
secondary migration has been observed, which is why
caution is needed in highly osteoporotic bone. Split frac-
tures (Magerl types A2 and A3.2) are not suited for stand-
alone VP, as the bone cements only can reliably neutralise
axially applied forces but not shear forces that occur in this
type of fracture. In elderly patients, superior burst fractures
without a split component (A3.1) can be treated with stand-
alone cementation as, in this group of patients, the adjacent
intervertebral disc is often already dehydrated and no
secondary segmental instability or discogenic pain is to be
expected. BKP is helpful to achieve anatomic reposition of the
endplate; whether this influences the survival of the disc and
preserves segmental mobility is the subject of ongoing
research, but, often, a spontaneous fusion to the next segment
is observed (Fig. 1). All complete burst- (A3.3) and B- and
C-type fractures require additional instrumentation.
Fig. 1 Incomplete superior burst fracture of T12 (45-year-old
male patient) treated with vertebral body stent and polymethylmeth-
acrylate bone cement (PMMA). a Standing preoperative radiograph.
b, c Preoperative computed tomography (CT) shows persistent
kyphosis, destruction of the anterior part of the endplate, intact
posterior wall and pedicles. d First postoperative standing radiograph
with reduction of the segmental kyphotic deformity from 30 to 10.
e Loss of intervertebral disc height at 2 months follow up and increase
of segmental kyphosis to 13. f ‘Spontaneous’ fusion at 6 months
follow up between T11 and T12, with segmental kyphosis of 15
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Techniques
Vertebroplasty
Percutaneous VP is a straightforward augmentation tech-
nique where the bone cement is directly injected via
cannulas of 8–11G diameter. The technique is indicated for
the treatment of simple compression fractures, haeman-
giomas and osteolytic neoplasms, where height restoration
is not the primary goal but, rather, the prevention of further
segmental or spinal malalignment, pain reduction,
improvement of physical function and QoL. The inter-
vention is performed under local or general anaesthesia in
the prone patient position and the cannulas are placed via a
transpedicular (lumbar) or extrapedicular (thoracal)
approach into the anterior third of the vertebral body. Both
mono- or bilateral approaches are possible; we use a
bilateral approach for fractured vertebrae and a monolateral
approach for prophylactic augmentation of intact vertebra
that are at high risk for collapse. Correct placement of the
cannulas is crucial and should be performed under biplanar
fluoroscopic control or CT guidance; dependent on surgeon
preference, the cannulas are introduced directly or over
previously placed guide wires. High-viscous bone cement,
usually PMMA, is injected into the vertebral body under
fluoroscopy control [7], without the creation of a void,
unlike in BKP. Depending on the type of cement and initial
viscosity, the application is performed either with 1- or
2-cm2 syringes or special high-pressure delivery systems.
The recommended filling volume of 4–8 ml is dependent
on the size of the vertebra and the grade of osteoporosis.
Re-establishment of lost vertebral body height is not
possible with the procedure per se, but can possibly be
achieved with additional positioning manoeuvres [8].
Balloon kyphoplasty
Kyphoplasty was introduced in 1998 to restore vertebral
body height and help realign the spine, using an inflatable
balloon to reduce the fracture before the injection of
cement [9–11]. A bilateral (and in rare cases, monolateral)
approach (trans- or parapedicular) is chosen to insert a
working cannula into the posterior part of the vertebral
body. Biplanar fluoroscopy is used to insert the tools and
control the procedure (reaming, balloon inflation, cement-
ing). With reaming tools, two working channels within the
anterior aspect of the vertebral body are created and the
appropriate balloons are inserted, ideally centred between
the endplates in the anterior two-thirds of the vertebral
body. Once inserted, the balloons are inflated using visual
volume and pressure controls to reduce the compressed
vertebra and create a cavity. Inflation is stopped when the
pressure is raised above 250 psi, when the balloon contacts
the cortical surface of the vertebral body or expands
beyond the border of the vertebral body or if the vertebral
body height is restored. The balloons are sequentially
deflated and removed, and the remaining cavity is filled
with bone cement under continuous fluoroscopic control
(Fig. 2).
The pain relief and improvement of QoL experienced by
patients after KP appear to be equal to VP, at least in the
short term [12]. Restoration of approximately 70 of the
initial vertebral body height is reported, reducing the local
kyphosis significantly by up to 9.5 vertebral kyphosis
angle (VKA) [13–15]. Today, a large variety of BKP sys-
tems are available from many different producers.
Stentoplasty and other intravertebral-implant-assisted
techniques
Following deflation of the KP balloons, often, a loss of the
achieved reduction has to be observed. To prevent this loss
of vertebral body height and realignment after balloon
deflation in BKP, the Vertebral Body Stenting System
(VBS, Synthes GmbH, Oberdorf, Switzerland) was devel-
oped. It consists of a balloon-expandable metal stent
mounted on a balloon catheter. After balloon deflation, the
intrinsic mechanical stability of the expanded rigid stent
construct keeps the created cavity open until PMMA-based
cement is injected and has cured [16]. The stent consists of
a cobalt–chromium alloy, which is also used in coronary
and peripheral artery stenting.
Usually, two VBS are inserted bilaterally into the ver-
tebral body. To symmetrically expand both stents, they are
simultaneously inflated with contrast saline solution. The
expanded stent comes pre-crimped on the balloon and is
gradually expanded to its final diameter. After the balloon-
assisted stent expansion is sufficient, the balloons are
deflated and retrieved. Finally, PMMA cement is
injected into the mesh structures to produce a stent-rein-
forced cement implant within the treated vertebral body
(Fig. 3).
Similar systems are the Kiva VCF Treatment System
(Benvenue Medical, Santa Clara, CA, USA), which uses a
polyetheretherketone (PEEK) coil instead of an expandable
cage. The StaXx Expandable Device (Spine Wave, Shel-
ton, CT, USA), which uses an expandable PEEK spacer,
SPIDER Somatoplasty System (Sintea Biotech, Miami
Beach, FL, USA) and OsseoFix (Alphatec Spine, Carlsbad,
CA, USA) are examples of stent-like expansion systems for
the treatment of VCF without cement augmentation.
Lordoplasty
In 2006, Orler et al. [17] introduced the concept of lor-
doplasty, a cost-effective, minimally invasive cement
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augmentation technique that allows kyphosis correction of
wedge-shaped VCF by the principles of ligamentotaxis, as
it is used by an internal fixateur. The fractured and the
adjacent vertebrae are bipedicular, instrumented with VP
cannulas and the fracture is reduced indirectly by applying
a lordotic moment via the cannulas and the facets as hyp-
omochlion (Fig. 4). It is possible to combine this technique
with a BKP or stentoplasty procedure to facilitate fracture
reduction of impressed or comminuted endplates. The
achieved mean correction of the VKA of 15 and 10 for
the bisegmental angle is larger than that reported for VP,
KP and VBS: VP follow up studies have shown reduction
of the VKA of between 1.7 and 6.6 [12, 15, 18]. This
effect is explained by the spontaneous fracture reduction
when placing the patient in the prone position. The
reported VKA correction by KP is between 4.8–9.5 [12,
13, 19–22]) and 5.2–7.3 by VBS, although these values
are based on small heterogenic groups.
Compared to BKP, lordoplasty is 6–10 times less
expensive. Moreover, the decision for reduction can be
made intraoperatively.
Cement augmentation as an adjuvant tool
with instrumentation
As adjuvant therapy, cement augmentation (vertebroplasty/
kyphoplasty) is used in the treatment of anterior unstable type A
and B fractures in addition to short-segment dorsal stabilisation
(Fig. 5). New data show that augmentation seems to provide
enough stability to support the anterior column. Compared to
combined anterior/posterior approaches, which impose addi-
tional strain for the patient, resources augmentation is less
invasive, with less morbidity and shorter hospitalisation [23–
25]. Especially for aged patients where no implant removal is
planned, this seems to be a valid alternative to anterior surgery.
Fig. 2 Balloon kyphoplasty
(BKP). An 83-year-old female
patient with an old vertebral
compression fracture (VCF) of
T12 presenting as vertebra plana
on standing preoperative
radiographs (a). b Vacuum sign
in the supine position at CT
scanning indicates persisting
mobility. c, d Intraoperative
monitoring of kyphosis
correction by the inflation of
two transpedicularly introduced
balloons (SynFlate, DePuy
Synthes). After deflation of the
balloons, usually, some loss of
reduction is observed.
e, f Filling of the resulting void
with 9 cc of high viscous
PMMA
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Complications
The use of PMMA in the described augmentation tech-
niques must be done with caution. There are a number of
potential serious complications that may occur with the
intraosseous injection of cement.
The risk of extraosseous cement leakage in various
series ranged between 3 and 74 % [12, 26–29], with
resultant neurological deficits such as radiculopathy and
cord compression occurring in 0–3.7 % and 0–0.5 %,
respectively [12, 26–28]. The risk of pulmonary embolism
lies between 3.5 and 23 % [30–33].
Fig. 3 Stentoplasty. A 68-year-
old male patient with a T12
VCF after minor trauma.
a Partial correction of the
vertebral kyphosis angle (VKA)
to 16 by prone positioning.
b Correction to 3 VKA after
slow and stepwise inflation of
the stent/balloon system (VBS,
DePuy Synthes). c The
expanded stent prevents a
secondary loss of reduction
when deflating the balloon.
d Filling of the void with 11 cc
of high-viscous PMMA; final
VKA of 4
Fig. 4 Lordoplasty—kyphosis correction by ligamentotaxis. A
76-year-old female patient with a non-traumatic T10 compression
type fracture. a In the prone position, a VKA of 13 persists
(intraoperative fluoroscopy). b Application of a lordotic moment via
the cannulas of the adjacent vertebra results in a VKA of 2. In this
case of known osteoporosis, the adjacent levels were cemented prior
to the repositioning manoeuvre. c Standing X-ray 6 months after the
intervention
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The leakage rate in KP is reported to be significantly
lower compared to in VP [12, 15], due to the cavity created
by the balloon allowing low-pressure and higher-viscosity
controlled cement filling. Once the cavity is filled, the
leakage behaviour is similar to VP [10]. Besides the bone
structure of the spine, the viscosity of the PMMA cement is
the major risk factor for cement leakages [34]. By adapting
the application technique, it is possible to influence the
viscosity of the PMMA cement using the temperature
gradient between body and room temperature, which
accelerates the polymerisation process in the vertebral
body. In a standard model, leakage can be significantly
reduced by the sequential application of small cement
amounts. Possible leakage paths are blocked before re-
application of the low-viscous cement [35]. Moreover, the
development of high-viscous PMMA cements have
reduced the rate of cement leakages significantly, resulting
in the disadvantage of the need for high-pressure injection
devices that are more expensive and lack tactile feedback.
The injection of any material into cancellous bone
inevitably displaces bone marrow into the circulation and
creates some pulmonary fat embolism. To prevent pul-
monary symptoms, the number of augmented vertebrae
during prophylactic multi-segmental VP should be limited
to six levels per session or 25–30 cc of PMMA [36]. In a
sheep model, it could be shown that lavage of the bone
marrow prior to VP prevents cardiovascular complications,
reduces injection pressures and allows a better control of
cement distribution, with less leakage [37, 38].
Discussion
More than 2,300 studies addressing cement augmentation
in spinal surgery have been published and there is still
ongoing debate as to whether VP or KP is more effective in
pain management compared to non-operative treatment.
This is remarkable, given that this treatment has been
performed very frequently for over 20 years now and it is
especially difficult to understand for surgeons who expe-
rience regularly the dramatic reduction of pain after the
intervention. The majority of these studies conclude to be
in favour for cement augmentation, but they have severe
limitations in their study design, being mostly retrospective
case series. The reason for this may be found in the het-
erogeneous and aged patient population and also the broad
spectrum of specialists who perform the augmentation
(orthopaedic/neurosurgical spine surgeons, general and
trauma surgeons, radiologists).
Two randomised controlled trials (RCTs) published in
the New England Journal of Medicine in 2009 [39, 40]
could not significantly demonstrate the benefit of VP
compared to a seemingly sham intervention, have lead to
the ongoing debate and may be responsible for the recently
experienced decrease of VP and KP since 2009 [41].
Although, compared to earlier publications, these studies
were superior with regards to study design (double-blinded
prospective randomised controlled trials), several limita-
tions reduce the validity of the conclusions; especially,
patient selection is one of the most criticised points, as
many fractures were non-acute and the type of pain was not
defined, ergo, it was possible that patients with other
painful spinal conditions were included with no potential to
benefit from the VP (but maybe from the sham intervention
that consisted of an injection of local anaesthetics). Further
it is remarkable that a majority of the eligible patients
refused to participate in the trials and a high rate of
crossover within the groups was observed, which may have
led to a selection bias and resulted in a relatively small
number of patients finally available for analysis. These
studies also demonstrate that randomised controlled trials
may not be the ideal study design when the effectiveness of
Fig. 5 A 72-year-old male patient with M. Bechterew and an
unstable type B fracture of the ankylosed spine at T11/12. a Standing
radiographs shows a relevant collapse of T12 that results in a large
ventral defect after alignment in the supine position for the CT scan
(b). The fracture was treated with cement-augmented stabilisation and
filling of the anterior defect with PMMA (c, d)
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a surgical intervention should be investigated, especially if
the criteria are not defined by surgeons. Similar to the
dosage of a pharmacological agent, the amount of injected
PMMA is very important, and the experience and tech-
nique of the surgeons are the relevant factors for a suc-
cessful intervention. The used amount of cement in these
New England Journal of Medicine studies are either not
documented or have a filling volume of only 2.8 ml per
vertebra below the recommendations or reported volumes
from other studies and, interestingly, also violated their
own study protocol [12, 42].
In the course of these New England Journal of Medicine
publications, better designed studies have been performed
and patient selection has become more restrictive to
patients with persisting pain clearly related to the acute
fracture. In such a subgroup, the Vertos II randomised
controlled trial, for example, could demonstrate significant,
immediate and lasting pain relief in the VP group as
compared to conservative treatment. The FREE study
compared KP against non-operative treatment with similar
inclusion criteria as the Vertos II trial and reported a sig-
nificantly superior pain relief at all time points over 2 years
[43, 44]. Rousing et al. [45] found a significant pain
reduction in the VP group compared to conservative
treatment only in the initial phase and similar results after 1
year. Papanastassiou et al. found, for their systematic
review, 27 prospective, multiple-arm studies with cohorts
of more than 20 patients (level of evidence I or II) and
concludes that VP and KP are superior with regard to pain
relief and the occurrence of new vertebral fractures as
compared to conservative treatment [15]. The reduced rate
of subsequent fractures contradicts the common belief that
the introduction of PMMA unfavourably alters spinal
biomechanics and increases the risk for subsequent frac-
tures [46]. Only intradiscal cement leakage, index fracture
at the thoracolumbar junction and male gender have been
identified as risk factors for subsequent fractures [18, 47,
48]. The epidemiological data suggest that the many
observed subsequent fractures are more the result of the
underlying disease and the biomechanical alterations where
the kyphotic deformity transfers the centre of gravity
ventrally and increases the load on the anterior column
[49–51]. The long-term results of interventions that spe-
cifically aim for restoration of the sagittal profile, such as
VBS or lordoplasty, may well reveal whether correction of
the kyphotic deformity is protective for subsequent
fractures.
The inconsistent results with regards to pain reduction
after VP points out that pain may not be the ideal outcome
parameter, as most of these aged patients have co-existing
other sources of back pain that are difficult to differentiate.
Several investigations, therefore, have focused on other
parameters which should better reflect the benefit of the
intervention: QoL can be assessed with a few simple
questions and is reported to increase significantly after VP
or KP. Again, as for pain and disability, the most benefit
was observed in the first 3 months after the intervention
[18, 29, 43, 52, 53]. Similarly, significantly less analgesics
had to be consumed in the groups that received treatment,
which is notable, as high-dosage analgesia-related com-
plications are to be expected in this aged high-risk popu-
lation [18, 52]. Dong et al. [54] could demonstrate a
significantly better pulmonary function in patients receiv-
ing VP or KP. The improvement was negatively correlated
with the kyphotic deformity and the best results were seen
in the KP group, where greater fracture reduction was
achieved. Earlier studies have already shown the relation-
ship between kyphotic deformity and impaired lung func-
tion [55] and between the presence of VCF or kyphotic
deformity and mortality due to pulmonary disease [2].
Mortality after VCF is known to be higher than in age-
matched cohorts and increases with the number of sus-
tained fractures [3, 4]. These factors may explain the
impressive results of Edidin et al. [56], who found, in a
large retrospective cohort of 858,987 aged patients with
VCFs, a significantly improved survivorship at 4 years
follow up for patients who received VP or KP (survival rate
of 60.8 % compared to 50.0 % for patients in the non-
operated cohort). Of course, the results of retrospective
case cohorts should not be overinterpreted, as no causal
relationship can be proven.
Conclusions
Since the first introduction of VP for vertebral haeman-
giomas in 1987 by Galibert et al. [6], cement augmentation
has been established as an effective treatment option for
osteoporotic or pathological VCFs with persisting pain
under conservative treatment.
Crucial factors for success are careful patient selection,
proper technique and choice of the ideal cement augmen-
tation option. Most compression fractures present a
favourable natural course with reduction of pain and re-
gainment of mobility after a few days. After the initial
diagnosis of a VCF, we, therefore, recommend to always
first try a conservative treatment with sufficient analgesia
and support in mobilisation. Seven to ten days after the
onset of pain, we perform a clinical and radiological con-
trol by a spine specialist to assess whether the kyphotic
deformity is progressive under load and if the pain shows a
mechanical quality as a hint for persisting fracture mobil-
ity. If there is a progressive collapse of the vertebra and
immobilisation due to mechanical pain, a percutaneous
intervention can be indicated and a computed tomography
(CT) or magnetic resonance imaging (MRI) scan is
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performed to rule out malignancy or a more complex
fracture. Fracture type, localisation, patient age and activ-
ity, and bone quality define which of the techniques
described above is the most ideal. Radiological follow up
with standing lateral radiographs are performed immedi-
ately after the first mobilisation and after 2 months to rule
out subsequent fractures, which are known to occur mainly
in the initial phase after the index fracture.
Percutaneous cement augmentation for VCFs with pro-
gressive collapse and persisting pain is an effective treatment
option with regards to pain and disability reduction, improve-
ment of QoL, and ambulatory and pulmonary function. The
procedure has a low complication rate if the technical safety
aspects described above are respected and if performed by
experienced specialists. Which of the numerous modern
cement systems is used may be of secondary importance, as
long as the surgeon is aware of and used to the specific tech-
nical, biomechanical and rheological properties of the system.
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